Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03019757 · ClinicalTrials.gov registry record
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
A clinical trial of Parkinson's Disease and Alzheimers Disease, sponsored by Douglas Scharre.
- Recruiting
- Registry status
- 76
- Enrollment target
- 1
- Study location
NCT03019757: Recruiting study of Parkinson's Disease and Alzheimers Disease, sponsored by Douglas Scharre.
NCT03019757 is a study of Parkinson's Disease and Alzheimers Disease that is actively recruiting participants, run by Douglas Scharre. The registered enrollment target is 76 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03019757, a study of Parkinson's Disease and Alzheimers Disease, is actively recruiting participants, sponsored by Douglas Scharre.
- RECRUITING
- Registry status
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.
Primary Outcome
Global neuropsychological measure
Conditions Studied
Interventions
- RADIATION DaTscan
- RADIATION F18-AV-45
- RADIATION FDG-PET
- GENETIC APOE genotype
- PROCEDURE Polysomnogram
Study Locations (1)
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2018-08-30 |
| Est. Completion | 2026-12 |
What NCT03019757 shows while recruiting
NCT03019757 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (88% lower).
The record links to 3 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 5 interventions - of which DaTscan is the first listed.
NCT03019757 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03019757 about?
NCT03019757 is a clinical study titled "Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease". The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.
What is the current status of trial NCT03019757?
This trial is currently recruiting. The enrollment target is 76 participants. The study started on 2018-08-30. Estimated completion is 2026-12.
What conditions does trial NCT03019757 study?
This clinical trial studies the following conditions: Parkinson's Disease, Alzheimers Disease, Lewy Body Dementia.
What interventions are being tested in trial NCT03019757?
The interventions under investigation include: DaTscan (RADIATION), F18-AV-45 (RADIATION), FDG-PET (RADIATION), APOE genotype (GENETIC), Polysomnogram (PROCEDURE).
Who is sponsoring clinical trial NCT03019757?
This trial is sponsored by Douglas Scharre, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03019757 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03019757's enrollment target sits among peer trials
76 65th of 158 higher than 94 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
RECRUITING · NA
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
Deep Brain Stimulation for Visuomotor Function in Parkinson's Disease
RECRUITING
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease
RECRUITING · NA
-
PET Imaging Evaluation of [11C]SY08
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
- NCT04109638 · 76 participants · NA
Pulsed Electromagnetic Field (PEMF) Therapy for Post-operative Pain Following Orthopedic Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI